Technical Analysis for TRGNF - Transgene Sa Ord

Grade Last Price % Change Price Change
grade F 1.91 4.95% 0.0900
TRGNF closed up 4.95 percent on Friday, September 13, 2019, on 36 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
See historical TRGNF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 4.95%
Narrow Range Bar Range Contraction 4.95%
Lower Bollinger Band Walk Weakness 4.95%
New 52 Week Low Weakness 4.95%
Older signals for TRGNF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with, Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; and collaboration and licensing agreement with Valneva; and a strategic collaboration with NEC Corporation. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Biotechnology Cancer Life Sciences Treatment Of Cancer Solid Tumors Infectious Diseases Cancers Health Care Non Small Cell Lung Cancer Glioblastoma Virotherapy Liver Cancer Treatment Of Non Small Cell Lung Cancer Biotechnology Companies Oncolytic Virus Chronic Hepatitis B Human Papilloma Virus Transgene Sa Experimental Cancer Treatments Treatment Of Liver Cancer

Is TRGNF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 4.26
52 Week Low 1.82
Average Volume 1,942
200-Day Moving Average 0.0000
50-Day Moving Average 3.3800
20-Day Moving Average 3.0386
10-Day Moving Average 2.6920
Average True Range 0.1986
ADX 20.65
+DI 25.8645
-DI 67.1656
Chandelier Exit (Long, 3 ATRs ) 3.0992
Chandelier Exit (Short, 3 ATRs ) 2.4158
Upper Bollinger Band 4.1296
Lower Bollinger Band 1.9476
Percent B (%b) -0.02
BandWidth 71.8094
MACD Line -0.3596
MACD Signal Line -0.1999
MACD Histogram -0.1597
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.9100
Resistance 3 (R3) 1.9100 1.9100 1.9100
Resistance 2 (R2) 1.9100 1.9100 1.9100 1.9100
Resistance 1 (R1) 1.9100 1.9100 1.9100 1.9100 1.9100
Pivot Point 1.9100 1.9100 1.9100 1.9100 1.9100
Support 1 (S1) 1.9100 1.9100 1.9100 1.9100 1.9100
Support 2 (S2) 1.9100 1.9100 1.9100 1.9100
Support 3 (S3) 1.9100 1.9100 1.9100
Support 4 (S4) 1.9100